PHOENIX, June 15,
2022 /PRNewswire/ -- Creative Medical Technology
Holdings, Inc. ("Creative Medical Technology" or the "Company")
(NASDAQ: CELZ), a leading commercial stage biotechnology company
focused on a regenerative approach to immunotherapy, urology,
neurology, and orthopedics, today announced that the Company has
signed an agreement with Greenstone Biosciences Inc. in
Palo Alto, CA for the development
of a human induced pluripotent stem cell (iPSC) pipeline for
the Company's ImmCelz® platform. This project will be
identified as iPScelzTM for future reference.
Dr. Joseph C. Wu, co-founder of
Greenstone Biosciences remarks, "This is a great collaboration that
translates our expertise in iPSC technology to accelerate therapies
that improve patient care – fast-tracking bench to bedside." Dr. Wu
is the Director of the Stanford Cardiovascular Institute and the
Simon H. Stertzer, MD, Professor of Medicine & Radiology at
Stanford University.
Timothy Warbington, President and
CEO of the Company, commented, "We are excited to complement and
expand our current work with the addition of Dr. Joseph Wu and the Greenstone team at Alexandria Center for Life
Sciences (ACLS). Greenstone brings extensive experience
in the development of iPSC and related technologies. In combination
with work continuing at the University of
Miami, we believe that our ImmCelz® platform has enormous
potential to improve outcomes for patients across multiple
indications, including Stroke, Type I Diabetes, Heart Disease,
Liver Disease, and Kidney Disease."
Human iPSc's are genetically reprogrammed to differentiate into
a wide array of human cell and tissue types, possess the
ability to proliferate almost indefinitely in culture,
and represent a single source of cells that could be used to
replace those lost to damage or disease. Beyond the
therapeutic benefits offered by iPSC, the next generation
iPScelzTM pipeline for ImmCelz® will enable the
ability for large scale production and sustainability, while
helping to reduce long term costs of manufacturing.
About ImmCelz®
ImmCelz®, which is protected by trade secrets and published U.S.
patents, utilizes adult stem cells derived from qualified donors to
endow specific properties to the patient's immune cells. After
the patient's harvested cells are incubated with the Company's
cell-free reprogramming "cocktail", the cells are re-injected back
into the patient. These "supercharged" cells subsequently
"educate" other cells of the immune system to stop attacking the
body, while preserving the ability to attack foreign pathogens.
About Greenstone
Biosciences
Greenstone Biosciences, Inc. (Palo
Alto, CA) is a biotechnology company co-founded by
Joseph C. Wu, MD, PhD and
Jade Chao, JD, MPH. The biotech
company specializes in clinical genomics, iPSC technology, AI/ML,
and drug development. Greenstone
has extensive knowledge and expertise in generating patient-derived
human iPSCs and differentiate to numerous cell types for disease
modeling and drug discovery. Greenstone Board Chairman Lip-Bu Tan of Walden
Catalyst Venture (WCV) is a long-term strategic partner. Mr. Tan
considers "this a wonderful and strategic partnership with CELZ."
For further information, please visit www.greenstonebio.com.
About Creative Medical Technology
Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage
biotechnology company specializing in stem cell technology in the
fields of immunotherapy, urology, neurology, and orthopedics. For
further information about the Company, please visit
www.creativemedicaltechnology.com.
Forward Looking
Statements
This news release may contain forward-looking statements
including but not limited to comments regarding the timing and
content of upcoming clinical trials and laboratory results,
marketing efforts, funding, etc. Forward-looking statements address
future events and conditions and, therefore, involve inherent risks
and uncertainties. Actual results may differ materially from those
currently anticipated in such statements. See the periodic and
other reports filed by Creative Medical Technology Holdings, Inc.
with the Securities and Exchange Commission and available on the
Commission's website at www.sec.gov.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/creative-medical-technology-holdings-announces-agreement-with-greenstone-biosciences-inc-for-development-of-a-next-generation-ipsc-pipeline-for-its-immcelz-immunotherapy-platform-301568167.html
SOURCE Creative Medical Technology Holdings, Inc.